Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03102320
Title	Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)
Acronym	ARCS-Multi
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Bayer
Indications	triple-receptor negative breast cancer gastroesophageal junction adenocarcinoma gastric adenocarcinoma lung adenocarcinoma cholangiocarcinoma thymic carcinoma pancreatic adenocarcinoma Advanced Solid Tumor
Therapies	Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| CHE \| CAN \| BEL \| AUS